Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing
- Publication Date :
- Publication Type : Journal Article
- Author(s) : Francesco Marchetti, Renato Cardoso, Connie L. Chen, George R. Douglas, Joanne Elloway, Patricia A. Escobar, Tod Harper Jr, Robert H. Heflich, Darren Kidd, Anthony M. Lynch, Meagan B. Myers, Barbara L. Parsons, Jesse J. Salk, Raja S. Settivari, Stephanie L. Smith-Roe, Kristine L. Witt, Carole Yauk, Robert R. Young, Shaofei Zhang & Sheroy Minocherhomji
- Journal Name : Nature Reviews Drug Discovery
The HESI GTTC is pleased to share its newest publication, “Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing,” published in Nature Reviews Drug Discovery. The commentary highlights the potential applications, advantages and challenges associated with implementing this emerging technology in nonclinical safety studies.
The article will be open access until 25 January 2023.
Read full article here:
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing. Marchetti et al. Nature Drug Discovery (January 2023). https://www.nature.com/articles/d41573-023-00014-y